Ragaini S.; Wagner S.; Marconi G.; Parisi S.; Sartor C.; Nanni J.; Cristiano G.; Talami A.; Olivi M.; Ocadlikova D.; Ciciarello M.; Corradi G.; Ottaviani E.; Papayannidis C.; Paolini S.; Vadakekolathu J.; Cavo M.; Rutella S.; Curti A., An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia, «BLOOD ADVANCES», 2022, 6, pp. 87 - 99 [Scientific article]Open Access
Ravaioli F.; Marconi G.; Martinelli G.; Dajti E.; Sartor C.; Abbenante M.C.; Alemanni L.V.; Nanni J.; Rossini B.; Parisi S.; Colecchia L.; Cristiano G.; Marasco G.; Vestito A.; Paolini S.; Bonifazi F.; Curti A.; Festi D.; Cavo M.; Colecchia A.; Papayannidis C., Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia, «CANCER MEDICINE», 2022, 11, pp. 618 - 629 [Scientific article]Open Access
Efficace F.; Gaidano G.; Petrucci M.T.; Niscola P.; Cottone F.; Codeluppi K.; Antonioli E.; Tafuri A.; Larocca A.; Potenza L.; Fozza C.; Pastore D.; Rigolin G.M.; Offidani M.; Romano A.; Kyriakou C.; Cascavilla N.; Gozzetti A.; Derudas D.; Vignetti M.; Cavo M., Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study, «THE LANCET. HEALTHY LONGEVITY», 2022, 3, pp. e625 - e638 [Scientific article]Open Access
Sartor C.; Arpinati M.; Chirumbolo G.; Dozza L.; Cristiano G.; Nanni J.; Marconi G.; Robustelli V.; Vigliotta I.; Parisi S.; Terragna C.; Testoni N.; Paolini S.; Martinelli G.; Curti A.; Cavo M.; Papayannidis C., Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment, «HEMATOLOGICAL ONCOLOGY», 2022, 40, pp. 734 - 742 [Scientific article]
Mazzocchetti G.; Poletti A.; Solli V.; Borsi E.; Martello M.; Vigliotta I.; Armuzzi S.; Taurisano B.; Zamagni E.; Cavo M.; Terragna C., BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles, «COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL», 2022, 20, pp. 3718 - 3728 [Scientific article]Open Access
Martino E.A.; Conticello C.; Zamagni E.; Pavone V.; Palmieri S.; Musso M.; Tacchetti P.; Mele A.; Catalano L.; Vigna E.; Bruzzese A.; Mendicino F.; Botta C.; Vincelli I.D.; Farina G.; Barone M.; Cangialosi C.; Mancuso K.; Rizziello I.; Rocchi S.; Falcone A.P.; Mele G.; Reddiconto G.; Garibaldi B.; Iaccino E.; Tripepi G.; Gamberi B.; Di Raimondo F.; Musto P.; Neri A.; Cavo M.; Morabito F.; Gentile M., Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials, «HEMATOLOGICAL ONCOLOGY», 2022, 0, pp. 0 - 0 [Scientific article]
Sonneveld P.; Zweegman S.; Cavo M.; Nasserinejad K.; Broijl A.; Troia R.; Pour L.; Croockewit S.; Corradini P.; Patriarca F.; Wu K.; Droogendijk J.; Bos G.; Hajek R.; Teresa Petrucci M.; Ypma P.; Zojer N.; Minnema M.C.; Boccadoro M., Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma, «HEMASPHERE», 2022, 6, pp. 786 - 786 [Scientific article]
Martello M.; Poletti A.; Borsi E.; Solli V.; Dozza L.; Barbato S.; Zamagni E.; Tacchetti P.; Pantani L.; Mancuso K.; Vigliotta I.; Rizzello I.; Rocchi S.; Armuzzi S.; Testoni N.; Marzocchi G.; Martinelli G.; Cavo M.; Terragna C., Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma, «BLOOD CANCER JOURNAL», 2022, 12, Article number: 15 , pp. 15 - 15 [Scientific article]Open Access
de Santis S.; Monaldi C.; Martelli M.; Mancini M.; Bruno S.; Castagnetti F.; Gugliotta G.; Polakova K.M.; Ernst T.; Maar D.; Corner A.; Cavo M.; Soverini S., CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. 289 - 290 [Scientific article]
Mancini M.; Monaldi C.; De Santis S.; Rondoni M.; Papayannidis C.; Sartor C.; Curti A.; Bruno S.; Cavo M.; Soverini S., Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells, «CANCERS», 2022, 14, pp. 738 - 750 [Scientific article]Open Access
Facon T.; San-Miguel J.; Dimopoulos M.A.; Mateos M.-V.; Cavo M.; van Beekhuizen S.; Yuan Z.; Mendes J.; Lam A.; He J.; Ammann E.; Kumar S., Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8), «ADVANCES IN THERAPY», 2022, 39, pp. 3868 - 3869 [Scientific article]
Dimopoulos M.A.; Moreau P.; Terpos E.; Mateos M.V.; Zweegman S.; Cook G.; Delforge M.; Hajek R.; Schjesvold F.; Cavo M.; Goldschmidt H.; Facon T.; Einsele H.; Boccadoro M.; San-Miguel J.; Sonneveld P.; Mey U., Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001)), «ANNALS OF ONCOLOGY», 2022, 33, pp. 988 - 988 [Scientific article]
Dimopoulos M.A.; Moreau P.; Terpos E.; Mateos M.V.; Zweegman S.; Cook G.; Delforge M.; Hajek R.; Schjesvold F.; Cavo M.; Goldschmidt H.; Facon T.; Einsele H.; Boccadoro M.; San-Miguel J.; Sonneveld P.; Mey U., Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322, «ANNALS OF ONCOLOGY», 2022, 33, pp. 117 - 117 [Scientific article]
Soverini, S.; De Santis, S.; Martelli, M.; Monaldi, C.; Castagnetti, F.; Gugliotta, G.; Papayannidis, C.; Mancini, M.; Bruno, S.; Venturi, C.; Machova Polakova, K.; Ernst, T.; Maar, D.; Corner, A.; Cavo, M., Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia, «LEUKEMIA», 2022, 36, pp. 2250 - 2260 [Scientific article]
Solimando A.G.; Malerba E.; Leone P.; Prete M.; Terragna C.; Cavo M.; Racanelli V., Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche, «FRONTIERS IN ONCOLOGY», 2022, 12, Article number: 973836 , pp. 1 - 17 [Scientific article]Open Access
